Johnson & Johnson announces new CEO
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[NEW YORK] Alex Gorsky will step down as chief executive of Johnson & Johnson in January, ceding the role to longtime company executive Joaquin Duato, the health care giant announced on Thursday.
Mr Gorsky, the CEO since 2012, is stepping aside "due to family health reasons," according to a company press release, which said he will stay on as executive chairman.
Mr Gorsky oversaw development of the company's one-shot Covid-19 vaccine. His tenure also coincided with a 60 per cent increase in research and development, the company said.
He has also been at the helm during a recent settlement with US states over opioids, agreeing to pay up to US$5 billion over nine years.
However, the company still faces litigation from plaintiffs who have sued J&J, alleging talcum products caused cancer.
Mr Duato, currently the vice chairman of the company's executive committee, will also join the company's board of directors.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
"I am honoured to serve as Johnson & Johnson's next CEO," Mr Duato said in the press release.
"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson's opportunity to play a key role in meaningfully improving the global trajectory of human health."
AFP
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report